MBX Biosciences Inc MBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MBX Biosciences to Participate in Upcoming November Investor Conferences
-
MBX Biosciences to Participate in Upcoming Investor Conferences
-
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
-
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
-
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
Trading Information
- Previous Close Price
- $49.61
- Day Range
- $49.70–53.06
- 52-Week Range
- $12.94–72.64
- Bid/Ask
- $44.89 / $52.56
- Shares Outstanding
- 48.16M
- Market Cap
- $2.53B
- Volume/Avg
- 522,210 / 529,455
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 63
- Website
- https://www.mbxbio.com
Valuation
|
Metric
|
MBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MBX
Financial Strength
|
Metric
|
MBX
|
|---|---|
Quick Ratio | 17.82 |
Current Ratio | 18.08 |
Interest Coverage | — |
Quick Ratio
MBX
Profitability
|
Metric
|
MBX
|
|---|---|
Return on Assets (Normalized) | −23.05% |
Return on Equity (Normalized) | −24.09% |
Return on Invested Capital (Normalized) | −27.74% |
Return on Assets
MBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|wrvRj^G | LOCK|GTtL | $127B | |||
| Moderna Inc
MRNA
| LOCK|&x#CcG$ | LOCK|XX | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<Gm^K## | LOCK|<Z!!% | $81B | |||
| argenx SE ADR
ARGX
| LOCK|hKb@FR% | LOCK|!> | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|RcDsK< | LOCK|$<V | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|j@c<<W$ | LOCK|?dFk | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%H&%^>@! | LOCK|XB>j | $27B | |||
| Incyte Corp
INCY
| LOCK|<sLk#X | LOCK|^WY | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|M%vmNGT | LOCK|&^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<?wyz#t | LOCK|KnS | $14B |
United States